ERBB2 and breast carcinoma: Together with the low concordance between the copy numbers and gene expression levels of ERBB2 in CMT (r = 0.09, measured in this cohort), unlike in human breast cancers (r = 0.857), we can assume a reduced role and limited clinical value for ERBB2 in CMT, as was previously proposed9,10.